{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-024675","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.561235+00:00","generated_at":"2026-05-22T01:03:36.142272+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arrowhead Q2 revenue $542.7M on Sarepta deal; plozasiran PDUFA Nov 18, 2025","bullets":["Q2 revenue of $542.7M (vs $0 prior year) driven by $825M Sarepta licensing deal ($500M cash + $325M equity).","GAAP diluted EPS $2.75 vs ($1.02) loss YoY; net income $370.4M.","FDA accepted plozasiran NDA for FCS with PDUFA date Nov 18, 2025; no advisory committee planned.","CFO Ken Myszkowski retiring May 13, 2025; succeeded by Daniel Apel.","Cash and investments $1.097B; company funded into 2028 with no near-term equity needs."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-024675","json":"https://secwatch.observer/filing/0001628280-25-024675.json","markdown":"https://secwatch.observer/filing/0001628280-25-024675.md","text":"https://secwatch.observer/filing/0001628280-25-024675.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000162828025024675/0001628280-25-024675-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000162828025024675/arwr-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T01:03:36.142272+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}